Developer docs
API playgroundTry for free, no card

Search company profiles

Sopharma

Full company profile

uuid0004y25

Namestring
Sopharma
Legal namestring
Sopharma AD (Софарма АД)
Websiteurl
sopharma.bg
Company typeenum
Public
Founded yearint
1932
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSofia, Bulgaria
HQ citystring
Sofia
HQ countrystring
Bulgaria
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceutical manufacturing, pharmaceutical contract manufacturing, drug licensing services, therapeutic area products, pharmaceutical export sales
Industry3 codes
1Generic Finished Dosage Form (FDF) Manufacturing
CodeHLAIABAHPrimaryYes
2Generic Hospital & Institutional Products
CodeHLAIABALPrimaryNo
3Drug Product Fill-Finish & Aseptic Manufacturing Services
CodeHLAAAKABPrimaryNo
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Sopharma generates revenue through manufacturing and selling generic pharmaceutical products. The company operates in the generic drug sector, selling products both domestically in Bulgaria and through export markets. Revenue for 2024 was 2,129,097 BGN '000 (consolidated).

sopharmagroup.com
2Contract Manufacturing
TypeProfessional Services
Description

Sopharma offers contract manufacturing and development services to business partners through its dedicated B2B partnerships section, providing manufacturing capabilities and development services to other pharmaceutical companies.

sopharmagroup.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sopharma manufactures and distributes generic pharmaceutical products across multiple therapeutic areas for both the Bulgarian domestic market and international export markets. In addition to its own branded generic portfolio, the company offers business-to-business contract manufacturing and product development services and engages in pharmaceutical licensing deals with partner companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Revenue growth of 41% year-on-year in Jan-May 2026
+1 more record
Product overview1 text field

Sopharma is a Bulgarian pharmaceutical company operating as a manufacturer in the generic drug sector. The company's portfolio includes generic pharmaceutical products distributed across therapeutic areas, complemented by business-to-business contract manufacturing and development services, as well as licensing deal partnerships. The product offering centers on generic pharmaceuticals with supporting manufacturing and licensing services for business customers.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Business-to-Business Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sopharma maintains dedicated business partnerships with pharmaceutical companies through contract manufacturing and development services. The company offers outsourcing manufacturing and development capabilities as well as licensing deals to other pharmaceutical businesses.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sopharma

Generic Pharmaceuticalssopharma.bg

Sopharma firmographics

Firmographics
Name
Sopharma
Legal name
Sopharma AD (Софарма АД)
Website
https://sopharma.bg
Company type
Public
Founded year
1932
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Sopharma industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro primary industry
Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
akta.pro secondary industries
Generic Hospital & Institutional Products (HLAIABAL), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

  • Generic pharmaceutical manufacturing
  • Pharmaceutical contract manufacturing
  • Drug licensing services
  • Therapeutic area products
  • Pharmaceutical export sales

Where Sopharma is headquartered

Location

Headquarters

HQ city
Sofia
HQ country
Bulgaria
HQ region
Europe

Offices1 record

Markets served

Sopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Sopharma generates revenue through manufacturing and selling generic pharmaceutical products. The company operates in the generic drug sector, selling products both domestically in Bulgaria and through export markets. Revenue for 2024 was 2,129,097 BGN '000 (consolidated).
  2. Contract Manufacturing: Sopharma offers contract manufacturing and development services to business partners through its dedicated B2B partnerships section, providing manufacturing capabilities and development services to other pharmaceutical companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Sopharma product offering

Product offering

Core offering

Sopharma manufactures and distributes generic pharmaceutical products across multiple therapeutic areas for both the Bulgarian domestic market and international export markets. In addition to its own branded generic portfolio, the company offers business-to-business contract manufacturing and product development services and engages in pharmaceutical licensing deals with partner companies.

Product overview

Sopharma is a Bulgarian pharmaceutical company operating as a manufacturer in the generic drug sector. The company's portfolio includes generic pharmaceutical products distributed across therapeutic areas, complemented by business-to-business contract manufacturing and development services, as well as licensing deal partnerships. The product offering centers on generic pharmaceuticals with supporting manufacturing and licensing services for business customers.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Revenue growth of 41% year-on-year in Jan-May 2026
  • +1 more outcomes

Companies that use Sopharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Sopharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Sopharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Business-to-Business PartnerscoreStrategic or Co-development PartnerSopharma maintains dedicated business partnerships with pharmaceutical companies through contract manufacturing and development services. The company offers outsourcing manufacturing and development capabilities as well as licensing deals to other pharmaceutical businesses.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Sopharma competitors and assessment

Company assessment

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Sopharma social profiles

Digital presence

Sopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sopharma leadership team

Management profile

Number of profiles

Profiles1 record

Sopharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sopharma M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sopharma

What does Sopharma do?

Sopharma manufactures and distributes generic pharmaceutical products across multiple therapeutic areas for both the Bulgarian domestic market and international export markets. In addition to its own branded generic portfolio, the company offers business-to-business contract manufacturing and product development services and engages in pharmaceutical licensing deals with partner companies.

Is Sopharma a public or private company?

Sopharma is a public company. It is classified as public and is currently operating.

When was Sopharma founded?

Sopharma was founded in 1932. It employs 1,001 to 5,000 people.

Where is Sopharma based?

Sopharma is headquartered in Sofia, Bulgaria, in the Europe region.

How does Sopharma make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing.

Does Sopharma have an API?

No public API is recorded for Sopharma.

What industry is Sopharma in?

Sopharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StIf EPS Growth Is Important To You, Sopharma AD (BUL:SFA) Presents An OpportunitySopharma AD has grown its earnings per share by 7.2% annually over the past three years, with revenue rising 17% to €1.5b. Insiders hold €137m in the stock and the CEO's pay is €356k, below the median for its market cap. The company is recommended for watchlist consideration.SeeNewsBulgaria's Sopharma sales soar 43% y/y in Jan-AugSopharma reported a 43% year-over-year revenue increase in Bulgaria's first eight months of 2026, driven by a 68% jump in export sales. Domestic sales rose 3%, while August revenue edged up 1% as domestic sales fell 3% and exports grew 4%.bne IntelliNewsSopharma becomes Bulgaria’s largest listed company after share-price rallySopharma became Bulgaria's largest listed company by market capitalisation after its shares rose nearly 20% over the past month to more than €1.24bn, overtaking Shelly Group at about €1.12bn. The company reported first-half revenue of over €730mn, up 11% year-on-year, and net profit of over €52mn, up 35%.CapitalЗначителен ръст в печалбата направи "Софарма" най-голямата компания на БФБSofarma overtook Shell to become Bulgaria's largest listed company after strong H1 results, with revenue exceeding 730 million euros and net profit over 52 million euros. Its share price rose 20% to over 1.24 billion euros, while Shell's capitalization fell to about 1.12 billion euros.SeeNewsBulgaria's Sopharma sales surge 41% in Jan-MayBulgarian pharmaceuticals producer Sopharma reported a 41% year-on-year surge in revenue for January-May 2026, driven by a 70% jump in export sales while domestic sales declined by 6%. In May alone, the company's sales revenue jumped 88% year-on-year, with export sales growing by 118%. Shares in Sopharma traded 0.52% higher at 1.94 euro following the announcement.SeeNewsBulgaria's Sopharma sells 4.6 mln own sharesBulgarian pharmaceutical company Sopharma sold approximately 4.6 million of its own shares for 8.73 million euro ($10.1 million) on the Bulgarian Stock Exchange on June 17. The shares were sold at an average price of 1.90 euro per share, representing 0.85% of the company's equity capital. Following the transaction, Sopharma holds 2.82 million own shares, equivalent to 0.52% of its share capital.PR NewswireSopharma, lider w branży farmaceutycznej, przeprowadza uaktualnienie oprogramowania do serializacją i urządzeń do agregacji farmaceutycznej przy wsparciu firmy SoftGroupSopharma, Bulgaria's largest pharmaceutical company, has partnered with SoftGroup to upgrade its serialization software and identification and tracking system, replacing a fragmented internal multi-market setup with the unified SoftGroup® SaTT platform. The agreement is aimed at bringing Sopharma's systems into compliance with Russian and European pharmaceutical traceability standards while enabling future global market expansion. SoftGroup will also provide consulting and support services to help Sopharma navigate evolving international serialization requirements.PR NewswireSopharma и SoftGroup обновляют программы для сериализации и оборудование для агрегацииBulgarian pharmaceutical company Sopharma has contracted SoftGroup to upgrade its serialization software and aggregation equipment with SoftGroup's SaTT tracking system, replacing Sopharma's existing multi-system setup. The upgrade aims to create a unified modern tracking platform compliant with Russian and European pharmaceutical tracking requirements, with SoftGroup also providing consulting and implementation support globally. The partnership is positioned as a strategic move to enhance Sopharma's product positioning across its markets in over 45 countries.PR NewswireFarmaceutický líder Sopharma aktualizuje svoj softvér pre serializáciu a agregačné zariadenia s podporou SoftGroupBulgarian pharmaceutical company Sopharma has selected SoftGroup to replace its existing serialisation software with the SoftGroup® SaTT solution. This strategic partnership aims to modernize Sopharma's traceability infrastructure to comply with regulatory requirements in Russia and Europe while improving operational efficiency.PR NewswireThe pharmaceutical leader Sopharma updates its Serialization Software and Aggregation equipment with the support of SoftGroupBulgarian pharmaceutical company Sopharma has partnered with SoftGroup to upgrade its serialization software and aggregation equipment using the SoftGroup® SaTT solutions, replacing its current heterogeneous system to meet track and trace requirements in Russia and Europe. The agreement includes consulting services and ongoing support for implementing dynamic global serialization requirements. The partnership is intended to provide Sopharma with a modern traceability platform and enable the company to position its product portfolio more competitively in global markets.